Published in J Lipid Res on February 02, 2010
MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol (2012) 3.78
MicroRNA regulation of lipid metabolism. Metabolism (2012) 2.15
MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol (2013) 2.04
MicroRNAs in lipid metabolism. Curr Opin Lipidol (2011) 1.79
Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab (2011) 1.53
microRNAs and cholesterol metabolism. Trends Endocrinol Metab (2010) 1.49
MicroRNAs in metabolic disease. Arterioscler Thromb Vasc Biol (2013) 1.33
The role of microRNAs in cholesterol efflux and hepatic lipid metabolism. Annu Rev Nutr (2011) 1.30
Control of cholesterol metabolism and plasma high-density lipoprotein levels by microRNA-144. Circ Res (2013) 1.25
Plasma levels of lipometabolism-related miR-122 and miR-370 are increased in patients with hyperlipidemia and associated with coronary artery disease. Lipids Health Dis (2012) 1.24
MicroRNAs and liver disease. Transl Res (2011) 1.21
Controlling SIRT1 expression by microRNAs in health and metabolic disease. Aging (Albany NY) (2010) 1.12
Lipid metabolism, apoptosis and cancer therapy. Int J Mol Sci (2015) 1.11
Roles of microRNA on cancer cell metabolism. J Transl Med (2012) 1.11
MicroRNA in Alzheimer's disease: an exploratory study in brain, cerebrospinal fluid and plasma. Biomarkers (2013) 1.00
MicroRNAs as regulators of metabolic disease: pathophysiologic significance and emerging role as biomarkers and therapeutics. Int J Obes (Lond) (2015) 0.98
MicroRNAs in the onset and development of cardiovascular disease. Clin Sci (Lond) (2014) 0.98
Dual role of microRNAs in NAFLD. Int J Mol Sci (2013) 0.95
MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma. Biomed Res Int (2014) 0.94
Mechanistic Role of MicroRNAs in Coupling Lipid Metabolism and Atherosclerosis. Adv Exp Med Biol (2015) 0.92
Ethanol facilitates hepatitis C virus replication via up-regulation of GW182 and heat shock protein 90 in human hepatoma cells. Hepatology (2013) 0.92
Pro-apoptotic miRNA-128-2 modulates ABCA1, ABCG1 and RXRα expression and cholesterol homeostasis. Cell Death Dis (2013) 0.92
Sphingolipids in obesity, type 2 diabetes, and metabolic disease. Handb Exp Pharmacol (2013) 0.91
MicroRNAs and lipoproteins: a connection beyond atherosclerosis? Atherosclerosis (2012) 0.90
Alcohol facilitates HCV RNA replication via up-regulation of miR-122 expression and inhibition of cyclin G1 in human hepatoma cells. Alcohol Clin Exp Res (2012) 0.89
MicroRNAs in bovine adipogenesis: genomic context, expression and function. BMC Genomics (2014) 0.88
MicroRNA Regulation of Cholesterol Metabolism. Cholesterol (2012) 0.88
Post-transcriptional regulation in metabolic diseases. RNA Biol (2012) 0.88
Liver microRNAs: potential mediators and biomarkers for metabolic and cardiovascular disease? Eur Heart J (2016) 0.87
Complexity of microRNA function and the role of isomiRs in lipid homeostasis. J Lipid Res (2013) 0.86
Postprandial regulation of hepatic microRNAs predicted to target the insulin pathway in rainbow trout. PLoS One (2012) 0.85
MicroRNAs involved in the lipid metabolism and their possible implications for atherosclerosis development and treatment. Mediators Inflamm (2014) 0.84
Deep sequencing of small RNA repertoires in mice reveals metabolic disorders-associated hepatic miRNAs. PLoS One (2013) 0.84
The colorectal tumor microenvironment: the next decade. Cancer Microenviron (2011) 0.83
MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis. Atherosclerosis (2015) 0.81
Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer. Cell Death Dis (2016) 0.81
Epigenetics and Cellular Metabolism. Genet Epigenet (2016) 0.80
MicroRNAs 9 and 370 Association with Biochemical Markers in T2D and CAD Complication of T2D. PLoS One (2015) 0.80
A genome-wide survey for prion-regulated miRNAs associated with cholesterol homeostasis. BMC Genomics (2012) 0.80
MicroRNA Dysregulation in Colon Cancer Microenvironment Interactions: The Importance of Small Things in Metastases. Cancer Microenviron (2011) 0.80
Discovery of novel and differentially expressed microRNAs between fetal and adult backfat in cattle. PLoS One (2014) 0.80
Epigenetic regulation of cholesterol homeostasis. Front Genet (2014) 0.80
Effects of hypoxic exercise training on microRNA expression and lipid metabolism in obese rat livers. J Zhejiang Univ Sci B (2014) 0.78
Caloric restriction-mediated induction of lipid metabolism gene expression in liver is enhanced by Keap1-knockdown. Pharm Res (2013) 0.78
The Regulation of Reverse Cholesterol Transport and Cellular Cholesterol Homeostasis by MicroRNAs. Biology (Basel) (2015) 0.78
MicroRNA-134 Contributes to Glucose-Induced Endothelial Cell Dysfunction and This Effect Can Be Reversed by Far-Infrared Irradiation. PLoS One (2016) 0.78
Genomic features and computational identification of human microRNAs under long-range developmental regulation. BMC Genomics (2011) 0.78
Epigenetic Activation of Wnt/β-Catenin Signaling in NAFLD-Associated Hepatocarcinogenesis. Cancers (Basel) (2016) 0.78
Circulating MicroRNAs as Biomarkers in Biliary Tract Cancers. Int J Mol Sci (2016) 0.76
Isocaloric Pair-Fed High-Carbohydrate Diet Induced More Hepatic Steatosis and Inflammation than High-Fat Diet Mediated by miR-34a/SIRT1 Axis in Mice. Sci Rep (2015) 0.76
Deep Sequencing and Screening of Differentially Expressed MicroRNAs Related to Milk Fat Metabolism in Bovine Primary Mammary Epithelial Cells. Int J Mol Sci (2016) 0.76
MicroRNA-370 Attenuates Hepatic Fibrogenesis by Targeting Smoothened. Dig Dis Sci (2015) 0.76
miR-31 Links Lipid Metabolism and Cell Apoptosis in Bacteria-Challenged Apostichopus japonicus via Targeting CTRP9. Front Immunol (2017) 0.75
MicroRNAs and Noncoding RNAs in Hepatic Lipid and Lipoprotein Metabolism: Potential Therapeutic Targets of Metabolic Disorders. Drug Dev Res (2015) 0.75
Are miRNA-103, miRNA-107 and miRNA-122 Involved in the Prevention of Liver Steatosis Induced by Resveratrol? Nutrients (2017) 0.75
Analysis of plasma miR-208a and miR-370 expression levels for early diagnosis of coronary artery disease. Biomed Rep (2016) 0.75
MicroRNAs in heart failure: Non-coding regulators of metabolic function. Biochim Biophys Acta (2016) 0.75
Analysis of miRNAs and their target genes associated with lipid metabolism in duck liver. Sci Rep (2016) 0.75
Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD. Int J Obes (Lond) (2017) 0.75
Making sense in antisense: therapeutic potential of noncoding RNAs in diabetes-induced vascular dysfunction. J Diabetes Res (2013) 0.75
Microtargeting cancer metabolism: opening new therapeutic windows based on lipid metabolism. J Lipid Res (2015) 0.75
Lipid overload during gestation and lactation can independently alter lipid homeostasis in offspring and promote metabolic impairment after new challenge to high-fat diet. Nutr Metab (Lond) (2017) 0.75
Role of microRNAs in obesity and obesity-related diseases. Genes Nutr (2017) 0.75
MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
The functions of animal microRNAs. Nature (2004) 64.85
Prediction of mammalian microRNA targets. Cell (2003) 53.70
Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer (2006) 46.47
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet (2004) 37.83
MicroRNAs modulate hematopoietic lineage differentiation. Science (2003) 30.05
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
Argonaute2 is the catalytic engine of mammalian RNAi. Science (2004) 22.86
The microRNAs of Caenorhabditis elegans. Genes Dev (2003) 17.70
Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet (2002) 17.20
A pancreatic islet-specific microRNA regulates insulin secretion. Nature (2004) 15.02
A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell (2006) 14.70
Identification of mammalian microRNA host genes and transcription units. Genome Res (2004) 14.63
Inhibition of translational initiation by Let-7 MicroRNA in human cells. Science (2005) 13.84
Identification of Drosophila MicroRNA targets. PLoS Biol (2003) 12.72
miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab (2006) 12.41
MicroRNA-dependent localization of targeted mRNAs to mammalian P-bodies. Nat Cell Biol (2005) 12.12
microRNAs: tiny regulators with great potential. Cell (2001) 11.23
Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev (2000) 9.09
Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature (2002) 8.77
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology (2001) 8.09
Role of LXRs in control of lipogenesis. Genes Dev (2000) 6.98
Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene (2006) 6.61
MicroRNAs in the human heart: a clue to fetal gene reprogramming in heart failure. Circulation (2007) 6.41
The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem (1997) 6.04
AGO1 defines a novel locus of Arabidopsis controlling leaf development. EMBO J (1998) 5.62
microRNAs join the p53 network--another piece in the tumour-suppression puzzle. Nat Rev Cancer (2007) 5.38
T cell lineage choice and differentiation in the absence of the RNase III enzyme Dicer. J Exp Med (2005) 5.26
Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat Neurosci (2004) 4.69
How do microRNAs regulate gene expression? Sci STKE (2007) 4.64
Dicing and slicing: the core machinery of the RNA interference pathway. FEBS Lett (2005) 4.63
NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology (2002) 4.44
Lipotoxic diseases. Annu Rev Med (2002) 4.16
New human and mouse microRNA genes found by homology search. FEBS J (2005) 3.88
The microRNA world: small is mighty. Trends Biochem Sci (2003) 3.86
Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology (2008) 3.68
Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology (2007) 3.06
Diagnosis and management of the metabolic syndrome. An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Executive summary. Cardiol Rev (2006) 2.99
Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucleic Acids Res (2006) 2.93
Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients. Hepatology (2001) 2.69
Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol Cell Biol (2001) 2.68
Inhibition of apolipoprotein B100 secretion by lipid-induced hepatic endoplasmic reticulum stress in rodents. J Clin Invest (2008) 2.58
Energizing miRNA research: a review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol Genet Metab (2007) 2.52
The role of AMP-activated protein kinase in the action of ethanol in the liver. Gastroenterology (2004) 2.50
MicroRNA-9 controls the expression of Granuphilin/Slp4 and the secretory response of insulin-producing cells. J Biol Chem (2006) 2.29
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology (2005) 2.25
MicroRNA and 3T3-L1 pre-adipocyte differentiation. RNA (2006) 2.00
Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol (2005) 1.71
Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature (2007) 1.66
Current perspectives in intronic micro RNAs (miRNAs). J Biomed Sci (2005) 1.53
Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol (1996) 1.46
Pathologic features associated with fibrosis in nonalcoholic fatty liver disease. Hum Pathol (2004) 1.32
MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease. Dig Liver Dis (2008) 1.21
Short-term overexpression of DGAT1 or DGAT2 increases hepatic triglyceride but not VLDL triglyceride or apoB production. J Lipid Res (2006) 1.20
Hepatic gene expression in histologically progressive nonalcoholic steatohepatitis. Hepatology (2003) 1.18
Molecular processes during fat cell development revealed by gene expression profiling and functional annotation. Genome Biol (2005) 1.16
Human microRNA (miR29b) expression controls the amount of branched chain alpha-ketoacid dehydrogenase complex in a cell. Hum Mol Genet (2005) 1.16
Acute hepatic steatosis in mice by blocking beta-oxidation does not reduce insulin sensitivity of very-low-density lipoprotein production. Am J Physiol Gastrointest Liver Physiol (2005) 1.15
microRNA-mediated silencing inside P-bodies. RNA Biol (2006) 1.08
Direct interaction between USF and SREBP-1c mediates synergistic activation of the fatty-acid synthase promoter. J Biol Chem (2006) 1.06
Inhibition of breast cancer cell growth in vitro and in vivo: effect of restoration of Wwox expression. Clin Cancer Res (2007) 1.05
Evidence that the AMP-activated protein kinase stimulates rat liver carnitine palmitoyltransferase I by phosphorylating cytoskeletal components. FEBS Lett (1998) 1.00
Preliminary assessment of the impact of microRNA-mediated regulation on coding sequence evolution in mammals. J Mol Evol (2006) 0.99
A dominant negative form of the transcription factor c-Jun affects genes that have opposing effects on lipid homeostasis in mice. J Biol Chem (2007) 0.91
P-bodies take a RISC. Nat Struct Mol Biol (2005) 0.82
Lipoprotein lipase: genetics, lipid uptake, and regulation. J Lipid Res (2002) 4.09
Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res (2008) 2.88
Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 2.49
Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest (2003) 2.39
Recipes for creating animal models of diabetic cardiovascular disease. Circ Res (2007) 2.34
Retinoid absorption and storage is impaired in mice lacking lecithin:retinol acyltransferase (LRAT). J Biol Chem (2005) 2.28
Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J Clin Invest (2007) 2.23
Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab (2013) 2.20
Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation (2012) 2.17
ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. J Clin Invest (2008) 2.16
Human aldose reductase expression accelerates diabetic atherosclerosis in transgenic mice. J Clin Invest (2005) 1.97
Hepatic overexpression of hormone-sensitive lipase and adipose triglyceride lipase promotes fatty acid oxidation, stimulates direct release of free fatty acids, and ameliorates steatosis. J Biol Chem (2008) 1.94
To drink or not to drink? N Engl J Med (2003) 1.79
Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model. Circ Res (2010) 1.73
PPARγ-induced cardiolipotoxicity in mice is ameliorated by PPARα deficiency despite increases in fatty acid oxidation. J Clin Invest (2010) 1.63
DGAT1 expression increases heart triglyceride content but ameliorates lipotoxicity. J Biol Chem (2009) 1.56
FoxOs integrate pleiotropic actions of insulin in vascular endothelium to protect mice from atherosclerosis. Cell Metab (2012) 1.46
Routes of FA delivery to cardiac muscle: modulation of lipoprotein lipolysis alters uptake of TG-derived FA. Am J Physiol Endocrinol Metab (2002) 1.42
Skeletal muscle-specific deletion of lipoprotein lipase enhances insulin signaling in skeletal muscle but causes insulin resistance in liver and other tissues. Diabetes (2008) 1.41
Diabetes adversely affects macrophages during atherosclerotic plaque regression in mice. Diabetes (2011) 1.35
Cardiac-specific knock-out of lipoprotein lipase alters plasma lipoprotein triglyceride metabolism and cardiac gene expression. J Biol Chem (2004) 1.34
The molecular basis of retinoid absorption: a genetic dissection. J Biol Chem (2008) 1.33
Very low density lipoprotein (VLDL) receptor-deficient mice have reduced lipoprotein lipase activity. Possible causes of hypertriglyceridemia and reduced body mass with VLDL receptor deficiency. J Biol Chem (2002) 1.32
Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J Biol Chem (2006) 1.32
Enhanced efferocytosis of apoptotic cardiomyocytes through myeloid-epithelial-reproductive tyrosine kinase links acute inflammation resolution to cardiac repair after infarction. Circ Res (2013) 1.27
Specific mutations in ABCA1 have discrete effects on ABCA1 function and lipid phenotypes both in vivo and in vitro. Circ Res (2006) 1.25
Deficiency of lipoprotein lipase in neurons modifies the regulation of energy balance and leads to obesity. Cell Metab (2011) 1.25
Chylomicron- and VLDL-derived lipids enter the heart through different pathways: in vivo evidence for receptor- and non-receptor-mediated fatty acid uptake. J Biol Chem (2010) 1.22
Altered hepatic lipid metabolism in C57BL/6 mice fed alcohol: a targeted lipidomic and gene expression study. J Lipid Res (2011) 1.21
Inflammatory cytokines and fatty acids regulate endothelial cell heparanase expression. Biochemistry (2004) 1.21
Analysis of mouse models of cytochrome c oxidase deficiency owing to mutations in Sco2. Hum Mol Genet (2010) 1.21
Apolipoprotein CIII overexpressing mice are predisposed to diet-induced hepatic steatosis and hepatic insulin resistance. Hepatology (2011) 1.21
Paradoxical coupling of triglyceride synthesis and fatty acid oxidation in skeletal muscle overexpressing DGAT1. Diabetes (2009) 1.17
Cross-linking and lipid efflux properties of apoA-I mutants suggest direct association between apoA-I helices and ABCA1. Biochemistry (2004) 1.17
Mechanism of glucose intolerance in mice with dominant negative mutation of CEACAM1. Am J Physiol Endocrinol Metab (2006) 1.16
Cross-inhibition of SR-BI- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and glyburide. J Lipid Res (2004) 1.15
Inactive lipoprotein lipase (LPL) alone increases selective cholesterol ester uptake in vivo, whereas in the presence of active LPL it also increases triglyceride hydrolysis and whole particle lipoprotein uptake. J Biol Chem (2001) 1.13
Addition of dietary fat to cholesterol in the diets of LDL receptor knockout mice: effects on plasma insulin, lipoproteins, and atherosclerosis. J Lipid Res (2006) 1.11
Lipids in the heart: a source of fuel and a source of toxins. Curr Opin Lipidol (2007) 1.10
DGAT1 deficiency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle. J Lipid Res (2011) 1.09
Cardiomyocyte lipids impair β-adrenergic receptor function via PKC activation. Am J Physiol Endocrinol Metab (2010) 1.09
Physical and functional interactions between liver X receptor/retinoid X receptor and Sp1 modulate the transcriptional induction of the human ATP binding cassette transporter A1 gene by oxysterols and retinoids. Biochemistry (2007) 1.09
Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy. J Pharmacol Exp Ther (2005) 1.09
Adipose-specific lipoprotein lipase deficiency more profoundly affects brown than white fat biology. J Biol Chem (2013) 1.08
Retinol-binding protein-deficient mice: biochemical basis for impaired vision. Biochemistry (2002) 1.08
Intestinal DGAT1 deficiency reduces postprandial triglyceride and retinyl ester excursions by inhibiting chylomicron secretion and delaying gastric emptying. J Lipid Res (2012) 1.06
Pathway of biogenesis of apolipoprotein E-containing HDL in vivo with the participation of ABCA1 and LCAT. Biochem J (2007) 1.06
Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk. Curr Atheroscler Rep (2004) 1.05
Regulation of mitochondrial biogenesis by lipoprotein lipase in muscle of insulin-resistant offspring of parents with type 2 diabetes. Diabetes (2012) 1.05
Deletions of helices 2 and 3 of human apoA-I are associated with severe dyslipidemia following adenovirus-mediated gene transfer in apoA-I-deficient mice. Biochemistry (2005) 1.04
Unexpected expression pattern for glycosylphosphatidylinositol-anchored HDL-binding protein 1 (GPIHBP1) in mouse tissues revealed by positron emission tomography scanning. J Biol Chem (2010) 1.03
Biophysical analysis of progressive C-terminal truncations of human apolipoprotein E4: insights into secondary structure and unfolding properties. Biochemistry (2008) 1.02
Structure and stability of apolipoprotein a-I in solution and in discoidal high-density lipoprotein probed by double charge ablation and deletion mutation. Biochemistry (2006) 1.02
Sphingolipids and cardiovascular diseases: lipoprotein metabolism, atherosclerosis and cardiomyopathy. Adv Exp Med Biol (2011) 1.01
Inhibition of c-Jun-N-terminal kinase increases cardiac peroxisome proliferator-activated receptor alpha expression and fatty acid oxidation and prevents lipopolysaccharide-induced heart dysfunction. J Biol Chem (2011) 1.00
Pancreatic beta-cell lipoprotein lipase independently regulates islet glucose metabolism and normal insulin secretion. J Biol Chem (2005) 1.00
Apolipoprotein B production reduces lipotoxic cardiomyopathy: studies in heart-specific lipoprotein lipase transgenic mouse. J Biol Chem (2003) 0.99
Peroxisome proliferator-activated receptor-γ activation prevents sepsis-related cardiac dysfunction and mortality in mice. Circ Heart Fail (2013) 0.99
Human aldose reductase expression accelerates atherosclerosis in diabetic apolipoprotein E-/- mice. Arterioscler Thromb Vasc Biol (2011) 0.99
Point mutations in apolipoprotein A-I mimic the phenotype observed in patients with classical lecithin:cholesterol acyltransferase deficiency. Biochemistry (2005) 0.99
Creating and curing fatty hearts. Curr Opin Clin Nutr Metab Care (2010) 0.98
Molecular interactions leading to lipoprotein retention and the initiation of atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 0.97
SR-BI mediates cholesterol efflux via its interactions with lipid-bound ApoE. Structural mutations in SR-BI diminish cholesterol efflux. Biochemistry (2005) 0.97
LDL receptor deficiency or apoE mutations prevent remnant clearance and induce hypertriglyceridemia in mice. J Lipid Res (2005) 0.96
Atherosclerosis in perlecan heterozygous mice. J Lipid Res (2004) 0.96
Hypertriglyceridemia-induced pancreatitis created by oral estrogen and in vitro fertilization ovulation induction. J Clin Lipidol (2008) 0.96
Mice with cardiac overexpression of peroxisome proliferator-activated receptor γ have impaired repolarization and spontaneous fatal ventricular arrhythmias. Circulation (2011) 0.95
Inflammatory signaling pathways regulating ApoE gene expression in macrophages. J Biol Chem (2007) 0.95
Poloxamer 407-mediated alterations in the activities of enzymes regulating lipid metabolism in rats. J Pharm Pharm Sci (2003) 0.94
Inhibition of hepatocyte nuclear factor 4 transcriptional activity by the nuclear factor kappaB pathway. Biochem J (2006) 0.93
Regulation of human apolipoprotein m gene expression by orphan and ligand-dependent nuclear receptors. J Biol Chem (2010) 0.93
Identification of the molecular target of small molecule inhibitors of HDL receptor SR-BI activity. Biochemistry (2007) 0.93
Cardiomyocyte specific deficiency of serine palmitoyltransferase subunit 2 reduces ceramide but leads to cardiac dysfunction. J Biol Chem (2012) 0.93
Mechanism of a transcriptional cross talk between transforming growth factor-beta-regulated Smad3 and Smad4 proteins and orphan nuclear receptor hepatocyte nuclear factor-4. Mol Biol Cell (2003) 0.92
Lipid-free structure and stability of apolipoprotein A-I: probing the central region by mutation. Biochemistry (2002) 0.92
Diacylglycerol acyl transferase 1 overexpression detoxifies cardiac lipids in PPARγ transgenic mice. J Lipid Res (2012) 0.91
A dominant negative form of the transcription factor c-Jun affects genes that have opposing effects on lipid homeostasis in mice. J Biol Chem (2007) 0.91
Sphingolipids, lipotoxic cardiomyopathy, and cardiac failure. Heart Fail Clin (2012) 0.91
Molecular mechanisms of type III hyperlipoproteinemia: The contribution of the carboxy-terminal domain of ApoE can account for the dyslipidemia that is associated with the E2/E2 phenotype. Biochemistry (2003) 0.90
Genetic dissection of retinoid esterification and accumulation in the liver and adipose tissue. J Lipid Res (2013) 0.90
Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT. Biochem J (2007) 0.90
Discrete roles of apoA-I and apoE in the biogenesis of HDL species: lessons learned from gene transfer studies in different mouse models. Ann Med (2008) 0.90
LCAT can rescue the abnormal phenotype produced by the natural ApoA-I mutations (Leu141Arg)Pisa and (Leu159Arg)FIN. Biochemistry (2007) 0.90
Endotoxin activates de novo sphingolipid biosynthesis via nuclear factor kappa B-mediated upregulation of Sptlc2. Prostaglandins Other Lipid Mediat (2010) 0.90
Acute lipoprotein lipase deletion in adult mice leads to dyslipidemia and cardiac dysfunction. Am J Physiol Endocrinol Metab (2006) 0.89
ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest (2016) 0.89
Carboxyl terminus of apolipoprotein A-I (ApoA-I) is necessary for the transport of lipid-free ApoA-I but not prelipidated ApoA-I particles through aortic endothelial cells. J Biol Chem (2011) 0.89
The carboxy-terminal region of apoA-I is required for the ABCA1-dependent formation of alpha-HDL but not prebeta-HDL particles in vivo. Biochemistry (2007) 0.89